Merck Serono's Cladribine Tablets for MS Approved in Russia PR Newswire GENEVA, July 12, 2010 GENEVA, July 12, 2010 /PRNewswire/ -- - First...
Merck Serono to Award Grant to Innovative Research Projects in Fertility - Grant Designed to Stimulate Innovation in The Field of Fertility...
Merck Serono: Data on Safinamide to Be Presented at the 14th MDS Meeting PR Newswire GENEVA, June 10, 2010 GENEVA, June 10, 2010 /PRNewswire/...
Merck Serono Resubmits U.S. Application for Cladribine Tablets as a Potential MS Therapy PR Newswire GENEVA, June 8, 2010 GENEVA, June 8, 2010...
Your Story, Your Voice, Your Achievements, Your Ideas This Is About Life, Real Life, Real MS - Merck Serono Launches Global Campaign to Raise...
International Thyroid Awareness Week 2010 to Focus on Thyroid Disorders and Pregnancy PR Newswire GENEVA, May 25, 2010 GENEVA, May 25, 2010...
Data from Merck Serono's Multiple Sclerosis Portfolio to be Presented at the 62nd Annual Meeting of the American Academy of Neurology - New Data...
GENEVA, Switzerland, October 10 /PRNewswire-FirstCall/ -- - Ranked Number 7 out of top 20 Employers Across Life Sciences Industry Merck Serono...
Delisting of Merck Serono Shares Expected on July 18, 2007 GENEVA, Switzerland, July 6 /PRNewswire-FirstCall/ -- The Civil Court of Basel has...
NEW YORK, April 26 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced...
GENEVA, Switzerland, April 5 /PRNewswire-FirstCall/ -- Merck Serono S.A. (NYSE:SRA)(Merck Serono) announced today that it has notified the New...
Delisting Planned in Switzerland and in the U.S. GENEVA, Switzerland, March 21 /PRNewswire-FirstCall/ -- The Civil Court of Basle-City announced...
GENEVA, Switzerland, March 21 /PRNewswire-FirstCall/ -- Merck Serono S.A. (virt-x: SEO and NYSE: SRA) announced today that the preliminary...
GENEVA, Switzerland, March 1 /PRNewswire-FirstCall/ -- Merck KGaA today announced preliminary fourth quarter and full year results for the...
GENEVA, Switzerland, February 28 /PRNewswire-FirstCall/ -- Dear Madam, Dear Sir, In conjunction with the year-end reporting of Merck KGaA...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.